Daniel Wik, MD
Physical Medicine & Rehabilitation · Columbus, NENPI 1093752883
Payments from drug & device makers
What this record shows
41 manufacturers reported payments, led by Biodelivery Sciences International, Inc. at 47.6% of the total. Reporting peaked in 2019 at $4,787 and has fallen 98.1% since, to $91 in 2025. Among physical medicine & rehabilitation clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 284 payments — averaging $28.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biodelivery Sciences International, Inc.$4K
- Supernus Pharmaceuticals, Inc.$519
- AbbVie$402
- Boston Scientific$385
- Lilly USA, LLC$311
- Biohaven Pharmaceuticals, Inc.$259
- plus $2K from 35 others
What the payments were for
- Speaking & faculty fees$3,63044%
- Food & beverage$4,53356%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BELBUCA$3,630
- SPECTRA WAVEWRITER$261
- Qutenza$156
- Saxenda$116
How this compares
$8,163 in reported general payments places this provider in the 95th percentile of 57 physical medicine & rehabilitation providers in Nebraska.
See all physical medicine & rehabilitation providers in Nebraska →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 46 | $88,198 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 572 | $82,722 |
| UbrelvyUbrogepant | 43 | $61,122 |
| QuliptaAtogepant | 48 | $57,668 |
| LinzessLinaclotide | 80 | $44,178 |
| Aimovig AutoinjectorErenumab-Aooe | 50 | $39,002 |
| Nucynta ErTapentadol Hcl | 32 | $30,611 |
| MovantikNaloxegol Oxalate | 53 | $20,739 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 37 | $19,779 |
| ZtlidoLidocaine | 22 | $18,194 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 584 | $17,980 |
| OxycontinOxycodone Hcl | 25 | $14,504 |
| Buprenorphine | 33 | $14,307 |
| TrintellixVortioxetine Hydrobromide | 24 | $12,805 |
| Xtampza ErOxycodone Myristate | 23 | $12,565 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta, Linzess | $402 | $162,968171 claims |
| PfizerNurtec Odt | $90 | $88,19846 claims |
| Collegium Pharmaceutical, Inc.Nucynta Er, Xtampza Er, Nucynta | $232 | $53,35870 claims |
| Redhill Biopharma Inc.Movantik | $25 | $20,73953 claims |
| Indivior Inc.Suboxone | $16 | $19,77937 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $108 | $18,19422 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $89 | $12,80524 claims |
| Novo NordiskOzempic | $167 | $11,45712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 57 physical medicine & rehabilitation providers in Nebraska.
Other physical medicine & rehabilitation in Columbus
- Kurt GoldOmaha$8K
- Jeremy GallantOmaha$2K
- David DiamantLincoln$2K
- Bo CuiOmaha$2K
- Thomas FrancoOmaha$2K
- Jiaxin TranLincoln$2K
- Adam KafkaLincoln$2K
- Zachary GustinOmaha$1K
- Paul KrabbenhoftLincoln$1K
- James KultOmaha$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.